Abstract: A lockable syringe, which includes a syringe body having a longitudinal axis and including a distal end and a proximal end, and a locking mechanism, wherein the locking mechanism is configured to be attached to the proximal end of the syringe body. The locking mechanism includes: a plunger having at least one distal plate, and a rod with visual elements for marking an unlock position; and a locking ring which is free in its rotation about the longitudinal axis of the syringe body, the locking ring has at least two visual indicators on its outer surface, and the locking ring has elements for blocking the plunger stroke in a locked position.

Abstract: A suxamethonium pharmaceutical composition including suxamethonium chloride and a succinic acid buffer. Also, a prefilled syringe thereof and a process of sterilizing the suxamethonium prefilled syringe. The composition and the prefilled syringe are useful as ready-to-use formulations, especially in emergency conditions, and present long shelf lives, even at room temperature.

Abstract: A lyophilized powder for the preparation of a solution for intravenous or parenteral injection comprising: from 1% to 30% of hydrocortisone hemisuccinate; from 40% to 98% of a bulking agent chosen from mannitol, trehalose, lactose, sucrose, raffinose or sorbitol; from 1% to 30% of a buffering agent; and use thereof for the preparation of a solution for intravenous or parenteral injection useful for the prevention or the treatment of the bronchopulmonary dysplasia in premature infants.

Abstract: The connecting device includes a mounting portion configured to be mounted on a vial; a female coupling end piece intended to be coupled to the male coupling end piece of a container; a perforation element configured to perforate a perforable closure element equipping the vial; a protective cap which is removable and which at least partially delimits an inner chamber in which the female coupling end piece extends; at least one passage orifice opening into the inner chamber and intended for the passage of a sterilization gas; and a closing membrane located upstream of the at least one passage orifice relative to a direction of circulation of the sterilization gas through the connecting device, the closing membrane being porous and permeable to the sterilization gas.

Abstract: A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, includes at least a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and a dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals. Single-dose formulations at a pH of between 7 and 7.8 includes a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin.

Abstract: A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, includes at least a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and a dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals. Single-dose formulations at a pH of between 7 and 7.8 includes a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin.

Abstract: A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, includes at least a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and a dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals. Single-dose formulations at a pH of between 7 and 7.8 includes a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin.

Abstract: A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, includes at least a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and a dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals. Single-dose formulations at a pH of between 7 and 7.8 includes a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin.

Abstract: Process of controlled free-radical polymerization in aqueous dispersion for the preparation of a block copolymer at least one block of which is a block of a halogenated polymer using molecular iodine and at least one oxidant whose solubility in water is at least 10 g/l for the synthesis of the first block of the block copolymer.

Abstract: A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, includes at least a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and a dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals. Single-dose formulations at a pH of between 7 and 7.8 includes a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin.

Abstract: Process of free-radical polymerization in aqueous dispersion for the preparation of polymers, employing (A) at least one ethylenically unsaturated monomer, one of which is employed as the principal monomer and is selected from styrene and its derivatives, acrylic acid and its derivatives, methacrylic acid and its derivatives, dienes, vinyl esters, vinyl ethers, vinylic pyridine derivatives, vinylsulphonic acid and its derivatives, vinylphosphonic acid and its derivatives, and N-vinyl monomers, (B) at least one free-radical initiator selected from diazo compounds, peroxides and dialkyldiphenylalkanes, (C) molecular iodine, and (D) at least one oxidizing agent whose solubility in water is at least 10 g/l, of which at least one may be the one (B); said process comprising the steps whereby (1) at least one fraction of each of compounds (A), (B), (C) and (D) is introduced into a reactor, and (2) the contents of the reactor are reacted while introducing into the reactor the remainder, where appropriate, of each of

Abstract: Process of controlled free-radical polymerization in aqueous dispersion for the preparation of a block copolymer at least one block of which is a block of a halogenated polymer using molecular iodine and at least one oxidant whose solubility in water is at least 10 g/l for the synthesis of the first block of the block copolymer.